Search Result

Results for "

MEFs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (4) AMPK (3) Apoptosis (8) Autophagy (5) DNA/RNA Synthesis (1) Dynamin (1) ERK (4) HDAC (1) HIF/HIF Prolyl-Hydroxylase (4) HSP (1) ICMT (1) MARK (2) Mitophagy (1) MMP (2) mTOR (1) NF-κB (1) Nuclear Factor of activated T Cells (NFAT) (1) p62 (1) PI3K (1) PIN1 (1) PKC (1) RAR/RXR (1) Ras (2) Reactive Oxygen Species (7) RIP kinase (2) Salt-inducible Kinase (SIK) (2) Small Interfering RNA (siRNA) (4) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (2) Infection (4) Inflammation/Immunology (7) Metabolic Disease (5) Neurological Disease (7)
Oligonucleotides:	Pre-designed siRNA Sets (4) siRNAs (4)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W187305

MASM7 1 Publications Verification	Others	Others
MASM7 is a mitofusin activator, and can achieve mitochondrial fusion via mitofusins. MASM7 can increase Mito AR with an EC₅₀ value of 75 nM in MEFs in concentration-responsively, and can promote mitochondrial fusion by directly activating MFN2 or MFN. MASM7 also demonstrates direct binding to the HR2 domain of MFN2 with K_d value of 1.1 μM .

HY-141591

CYT296	Others	Others
CYT296 is a target chromatin de-condensation compound. CYT296 can improve the induction of induced pluripotent stem cell (iPSCs) mediated by defined factors (OSKM) and induce an open chromatin state in Mouse Embryonic Fibroblast (MEFs) to facilitate somatic cell reprogramming. CYT296 can be used for cell replacement therapies and drug screening research .

HY-19350

BML-210 2 Publications Verification	HDAC Apoptosis	Cancer
BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC₅₀ of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice .

HY-P5891

TAT-SAMβA	PKC	Cardiovascular Disease
TAT-SAMβA is the peptide consist of RNAENFDRF (SAMβA; HY-P3429) conjugated to the cell penetrating TAT protein-derived peptide TAT_47–57. TAT-SAMβA is a selective antagonist of Mfn1-βIIPKC association. TAT-SAMβA protects mouse embryonic fibroblast cells (MEFs) against oxidative stress-induced cytotoxicity .

HY-160840

SPB-AAD	Others	Others
SPB-AAD is a BFPX probe. SPB-AAD has covalent capture of in vitro assembled MEF2/DNA and NFAT1/DNA complexes .

HY-RS08309

MEF2A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MEF2A Human Pre-designed siRNA Set A contains three designed siRNAs for MEF2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MEF2A Human Pre-designed siRNA Set A MEF2A Human Pre-designed siRNA Set A

HY-RS08310

MEF2B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MEF2B Human Pre-designed siRNA Set A contains three designed siRNAs for MEF2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MEF2B Human Pre-designed siRNA Set A MEF2B Human Pre-designed siRNA Set A

HY-RS08311

MEF2C Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MEF2C Human Pre-designed siRNA Set A contains three designed siRNAs for MEF2C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MEF2C Human Pre-designed siRNA Set A MEF2C Human Pre-designed siRNA Set A

HY-RS08312

MEF2D Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MEF2D Human Pre-designed siRNA Set A contains three designed siRNAs for MEF2D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MEF2D Human Pre-designed siRNA Set A MEF2D Human Pre-designed siRNA Set A

HY-N12760

Lobophorin CR-2	Others	Cancer
Lobophorin CR-2 is a lobophorin congener which induces UPR-associated gene expression, inhibits oral squamous cell carcinoma cell growth, and causes UPR-dependent cell death in MEF cells .

HY-147284

PI3K-IN-37	PI3K mTOR	Others
PI3K-IN-37 (Example 84.1) is a PI3K α/β/δ inhibitor with IC₅₀s of 6, 8, 4 nM, respectively. PI3K-IN-37 can also inhibit mTOR (IC₅₀=4 nM) .

HY-148052

RIPK3-IN-2	RIP kinase	Cancer
RIPK3-IN-2 is a RIP3 inhibitor. RIPK3-IN-2 can be used in diseases caused by or associate with activated necrotic pathways research .

HY-128034

PPIase-Parvulin inhibitor	PIN1	Cancer
PPIase-Parvulin inhibitor (compound B) is a cell-permeable inhibitor targeting PPIase Pin1 and Par14, with IC_{50_s} of 1.5 and 1.0 µM, respectively. PPIase-Parvulin inhibitor has anticancer activity and inhibits the growth and proliferation of mouse embryonic fibroblasts (MEFs) .

HY-120877

MRT199665	MARK Salt-inducible Kinase (SIK) AMPK Apoptosis	Cancer
MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC₅₀s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively . MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells . MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370 .

HY-120877A

(R)-MRT199665	MARK Salt-inducible Kinase (SIK) AMPK Apoptosis	Cancer
(R)-MRT199665 is an isomer of MRT199665 (HY-120877). MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC₅₀s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively. MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells. MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370 .

HY-124514

UC-857993	Ras ERK	Cancer
UC-857993 is a selective SOS1-Ras inhibitor (K_d=14.7 μM, His₆-SOS1_cat), suppressing catalytic activity. UC-857993 also inhibits ERK and Ras activation, suppresses the growth of mouse embryonic fibroblasts (MEFs) .

HY-153413

Kras4B G12D-IN-1	Ras	Cancer
Kras4B G12D-IN-1 is a Kras4B G12D inhibitor with anticancer effects. Kras4B G12D-IN-1 decreases Kras protein expression in mouse embryonic fibroblasts (MEF) expressing Kras4B G12D (WO2016179558A1, Comp 994566) .

HY-136386

N-Acetyl-D-cysteine 2 Publications Verification	Reactive Oxygen Species	Others
N-Acetyl-D-cysteine has antioxidant activities and scavenges ROS through the reaction with its thiol group, but cannot enter the glutathione metabolic pathway .

HY-120904

AMPK-IN-1	AMPK	Metabolic Disease
AMPK-IN-1 is an activator of AMPK (EC₅₀: 551 nM for isoform α2β2γ1). AMPK-IN-1 leads to eEF2 phosphorylation in a mTORC1-independent way .

HY-126214S

JH-RE-06-d6	DNA/RNA Synthesis	Cancer
JH-RE-06-d6 is deuterium labele JH-RE-06. JH-RE-06, a potent REV1-REV7 interface inhibitor (IC₅₀=0.78 μM; K_i=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy .

HY-136386R

N-Acetyl-D-cysteine (Standard)	Reactive Oxygen Species	Others
N-Acetyl-D-cysteine (Standard) is the analytical standard of N-Acetyl-D-cysteine. This product is intended for research and analytical applications. N-Acetyl-D-cysteine has antioxidant activities and scavenges ROS through the reaction with its thiol group, but cannot enter the glutathione metabolic pathway .

HY-131037

MB-0223	Dynamin	Cancer
MB-0223 is a potent and selective dynamin-related GTPase Drp1 partial inhibitor (IC₅₀=1.3 μM) over other dynamin family members, Opa 1 and dynamin-1 (IC₅₀>100 μM) .

HY-128341

ERK5-IN-2	ERK	Cardiovascular Disease Cancer
ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC₅₀s of 0.82 μM, 3 μM for ERK5 and ERK5 MEF2D, respectively. ERK5-IN-2 does not interact with the BRD4 bromodomain. ERK5-IN-2 suppresses both tumor xenograft growth and basic fibroblast growth factor (bFGF) driven Matrigel plug angiogenesis .

HY-139062

C6 Urea Ceramide C6 Ceramide (d18:1/6:0) Urea; Cer(d18:1/6:0) Urea; D-erythro-Urea-C6-Ceramide	Others	Cancer
C6 Urea Ceramide (C6 Ceramide (d18:1/6:0) Urea; Cer(d18:1/6:0) Urea) is an inhibitor of neutral ceramidase. It increases total ceramide levels in wild-type mouse embryonic fibroblasts (MEFs) and HT-29 colon cancer cells, but not in MEFs lacking neutral ceramidase. At concentrations of 5 and 10 μM, it inhibits proliferation of HT-29 cells and induces apoptosis and autophagy, but not in noncancerous RIE-1 cells. C6 Urea Ceramide decreases total β-catenin, increases phosphorylated β-catenin, and induces colocalization of β-catenin with the 20S proteasome in HT-29 and HCT116 cells, but not in RIE-1 cells. When administered at doses of 1.25, 2.5, and 5 mg/kg for five days, it reduces tumor growth and increases C16, C18, C20, and C24 ceramide levels in tumor tissues in the HT-29 mouse xenograft model.

HY-149709

ICMT-IN-35	ICMT	Cancer
ICMT-IN-35 (compound 10n) is a FTPA-triazole compound and ICMT inhibitor (IC₅₀=0.8 μM). ICMT-IN-35 is taken up by mammalian cells and can prevent K-Ras membrane localization and induce K-Ras mislocalization. Furthermore, ICMT-IN-35 is selectively cytotoxic against ICMT ^+/+ MEF cells and has low micromolar activity (IC₅₀=0.8 μM) against metastatic pancreatic cancer cell lines .

HY-124817

Col003 5 Publications Verification	HSP	Inflammation/Immunology
Col003 is a selective and potent inhibitor of Hsp47 and competitively binds to the collagen binding site on Hsp47 (IC₅₀=1.8 μM). Col003 discourages the interaction of Hsp47 with collagen and inhibits collagen secretion by destabilizing the collagen triple helix. Col003 can be used for the investigation of fibrosis

HY-115576

P62-mediated mitophagy inducer 4 Publications Verification PMI	p62 Mitophagy Autophagy	Neurological Disease Cancer
P62-mediated mitophagy inducer (PMI) is a P62-mediated mitophagy activator. P62-mediated mitophagy inducer activates mitochondrial autophagy without recruitment of Parkin or collapse of the mitochondrial membrane potential and remains active in cells lacking a fully functional PINK1/Parkin pathway. P62-mediated mitophagy inducer serves as a pharmacological tool to study the molecular mechanisms of mitosis, avoiding toxicity and some of the non-specific effects associated with the sudden dissipation of mitochondria lacking membrane potential .

HY-125402

GSK-843 3 Publications Verification GSK'843	RIP kinase Apoptosis	Inflammation/Immunology
GSK-843 (GSK'843) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC₅₀ of 8.6 nM, and inhibits kinase activity with an IC₅₀ of 6.5 nM. GSK-843 can be used for the research of inflammation .

HY-160493

PTK7/β-catenin-IN-6	Wnt β-catenin	Cancer
PTK7/β-catenin-IN-6 (Compound 03653) is an inhibitor for PTK7/β-catenin interaction, which inhibits the Wnt signaling pathway, and exhibits an anticancer activity against colorectal cancer (CRC) .

HY-115701

1-Stearoyl-2-15(S)-Hpete-Sn-Glycero-3-Pe 1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-phosphoethanolamine; 15(S)-HpETE-SAPE; 15(S)-hydroperoxyeicostetraenoic acid-SAPE	Others	Inflammation/Immunology
1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-Pe is a phospholipid that contains stearic acid (HY-B2219) at the sn-1 position and 15(S)-HpETE at the sn-2 position. It is produced via oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-Pe (SAPE) by 15-lipoxygenase (15-LO). 1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-Pe (0.6 and 0.9 μM) increases ferroptotic cell death in wild-type and Acsl4 knockout Pfa1 mouse embryonic fibroblasts (MEFs) treated with the GPX4 inhibitor RSL3.

HY-B0988

Deferoxamine mesylate Maximum Cited Publications 218 Publications Verification Desferrioxamine B mesylate; DFOM	Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species Apoptosis Akt	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .

HY-B1625

Deferoxamine Maximum Cited Publications 218 Publications Verification Deferoxamine B; Deferriferrioxamine B; Deferrioxamine	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species Apoptosis Akt Autophagy	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .

HY-P3513

β-Neo-Endorphin	ERK MMP	Neurological Disease
β-Neo-Endorphin is an endogenous opioid peptide. β-Neo-Endorphin is a hypothalamic “big” Leu-enkephalin of porcine origin. β-Neo-Endorphin shows activation of the Erk1/2, MMP-2 and MMP-9 .

HY-B0988R

Deferoxamine mesylate (Standard)	Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species Apoptosis Akt	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Deferoxamine (mesylate) (Standard) is the analytical standard of Deferoxamine (mesylate). This product is intended for research and analytical applications. Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .

HY-B1625R

Deferoxamine (Standard)	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species Apoptosis Akt Autophagy	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Deferoxamine (Standard) is the analytical standard of Deferoxamine. This product is intended for research and analytical applications. Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .

HY-P3513A

β-Neo-Endorphin acetate	ERK MMP	Neurological Disease
β-Neo-Endorphin acetate is an endogenous opioid peptide. β-Neo-Endorphin acetate is a hypothalamic "big" Leu-enkephalin of porcine origin. β-Neo-Endorphin acetate shows activation of the Erk1/2, MMP-2 and MMP-9 .

HY-10475G

AM580 CD336; NSC608001; Ro 40-6055	RAR/RXR	Cancer
AM580 (CD336) (GMP) is AM580 (HY-10475) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AM580 is a selective RARα agonist .

HY-117987

CPS-11 N-(Hydroxymethyl)thalidomide	Nuclear Factor of activated T Cells (NFAT) NF-κB Reactive Oxygen Species	Cancer
CPS-11 (N-(Hydroxymethyl)thalidomide) a Thalidomide (HY-14658) analogue, is a potent anti-cancer agent. CPS-11 inhibits NF-κB, activates NFAT, and repress cytokine expression through elevated ROS. CPS-11 exhibits a wider activity spectrum and higher potency against MM (multiple myeloma) cell lines .

AM580 (GMP) CD336 (GMP); NSC608001 (GMP); Ro 40-6055 (GMP)	Fluorescent Dye
AM580 (CD336) (GMP) is AM580 (HY-10475) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AM580 is a selective RARα agonist .

Cat. No.	Product Name	Type